2026-04-17T06:50:29Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4583272026-03-13T07:54:09Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Muñoz-Domínguez, Noelia author Roura, Santiago author Prat-Vidal, Cristina author Vives Armengol, Joaquim author Universitat Autònoma de Barcelona author 2021 Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management. Biomanufacturing Cardiac tissue engineering Clinical translation Extracellular vesicles Mesenchymal stromal cells Myocardial infarction Wharton's jelly Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit : an experienced view